Disease-causing mutations in the serpin antithrombin reveal a key domain critical for inhibiting protease activities

Journal of Biological Chemistry

Volumn 292, Issue 40, 2017, Pages 16513-16520

  Águila, Sonia ^a   Izaguirre, Gonzalo ^b   Martínez Martínez, Irene ^a,c   Vicente, Vicente ^a,c   Olson, Steven T ^a,b   Corral, Javier ^a,c  

^a HOSPITAL UNIVERSITARIO MORALES MESEGUER   (Spain)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CRYSTAL STRUCTURE; ENZYMES; STOICHIOMETRY;

CLOSE PROXIMITY; DOCKING SITES; FUNCTIONAL DOMAINS; PROTEASE ACTIVITIES; PROTEASE COMPLEX; PROTEASE INHIBITION; REACTIVE CENTER LOOPS; STABLE COMPLEXES;

SUBSTRATES;

ANTITHROMBIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; HEPARIN; PROTEINASE; SERINE PROTEINASE INHIBITOR; TRANSCRIPTION FACTOR IIA; THROMBIN;

ADULT; ANTITHROMBIN DEFICIENCY; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EMBRYO; ENZYME SUBSTRATE COMPLEX; FEMALE; GENE EXPRESSION; GENE TRANSLOCATION; GENETIC VARIABILITY; HEK293-EBNA CELL LINE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MIDDLE AGED; MUTATION; MUTATIONAL ANALYSIS; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEINASE INHIBITION; STOICHIOMETRY; THERMODYNAMICS; THERMOSTABILITY; WILD TYPE; YOUNG ADULT; AMINO ACID SUBSTITUTION; BLOOD CLOTTING DISORDER; CHEMISTRY; ENZYME ACTIVE SITE; GENETICS; MALE; METABOLISM; MISSENSE MUTATION; MOLECULAR DOCKING; PROTEIN SECONDARY STRUCTURE;

AMINO ACID SUBSTITUTION; ANTITHROMBIN PROTEINS; BLOOD COAGULATION DISORDERS, INHERITED; CATALYTIC DOMAIN; FACTOR XA; FEMALE; HUMANS; MALE; MOLECULAR DOCKING SIMULATION; MUTATION, MISSENSE; PROTEIN DOMAINS; PROTEIN STRUCTURE, SECONDARY; THROMBIN;

EID: 85030671094     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M117.787325     Document Type: Article

References (37)

1. Gils, A., and Declerck, P. J. (1998) Structure-function relationships in serpins: current concepts and controversies. Thromb. Haemost. 80, 531–541
2. Olson, S. T., Richard, B., Izaguirre, G., Schedin-Weiss, S., and Gettins, P. G. W. (2010) Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases: a paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors. Biochimie 92, 1587–1596
3. Olson, S. T., Björk, I., Sheffer, R., Craig, P. A., Shore, J. D., and Choay, J. (1992) Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions: resolution of the antithrombin conformational change contribution to heparin rate enhancement. J. Biol. Chem. 267, 12528 –12538
4. Johnson, D. J. D., Li, W., Adams, T. E., and Huntington, J. A. (2006) Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation. EMBO J. 25, 2029 –2037
5. Izaguirre, G., and Olson, S. T. (2006) Residues Tyr253 and Glu255 in strand 3 of -sheet C of antithrombin are key determinants of an exosite made accessible by heparin activation to promote rapid inhibition of factors Xa and IXa. J. Biol. Chem. 281, 13424 –13432
6. Izaguirre, G., Aguila, S., Qi, L., Swanson, R., Roth, R., Rezaie, A. R., Gettins, P. G. W., and Olson, S. T. (2014) Conformational activation of antithrombin by heparin involves an altered exosite interaction with protease. J. Biol. Chem. 289, 34049 –34064
7. Huntington, J. A., Read, R. J., and Carrell, R. W. (2000) Structure of a serpin-protease complex shows inhibition by deformation. Nature 407, 923–926
8. Rau, J. C., Beaulieu, L. M., Huntington, J. A., and Church, F. C. (2007) Serpins in thrombosis, hemostasis and fibrinolysis. J. Thromb. Haemost. 5, Suppl. 1, 102–115
9. Quinsey, N. S., Greedy, A. L., Bottomley, S. P., Whisstock, J. C., and Pike, R. N. (2004) Antithrombin: in control of coagulation. Int. J. Biochem. Cell Biol. 36, 386 –389
10. Chuang, Y. J., Gettins, P. G. W., and Olson, S. T. (1999) Importance of the P2 glycine of antithrombin in target proteinase specificity, heparin activation, and the efficiency of proteinase trapping as revealed by a P2 Gly 3 Pro mutation. J. Biol. Chem. 274, 28142–28149
11. Futamura, A., and Gettins, P. G. W. (2000) Serine 380 (P14) 3 glutamate mutation activates antithrombin as an inhibitor of factor Xa. J. Biol. Chem. 275, 4092– 4098
12. Johnson, D. J. D., and Huntington, J. A. (2004) The influence of hinge region residue Glu-381 on antithrombin allostery and metastability. J. Biol. Chem. 279, 4913– 4921
13. Caso, R., Lane, D. A., Thompson, E. A., Olds, R. J., Thein, S. L., Panico, M., Blench, I., Morris, H. R., Freyssinet, J. M., Aiach, M., et al. (1991) Antithrombin Vicenza, Ala 384 to Pro (GCA to CCA) mutation, transforming the inhibitor into a substrate. Br. J. Haematol. 77, 87–92
14. Devraj-Kizuk, R., Chui, D. H., Prochownik, E. V., Carter, C. J., Ofosu, F. A., and Blajchman, M. A. (1988) Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity. Blood 72, 1518 –1523
15. Lane, D. A., Olds, R. J., Conard, J., Boisclair, M., Bock, S. C., Hultin, M., Abildgaard, U., Ireland, H., Thompson, E., and Sas, G. (1992) Pleiotropic effects of antithrombin strand 1C substitution mutations. J. Clin. Invest. 90, 2422–2433
16. Águila, S, Navarro-Fernández, J., Bohdan, N., Gutiérrez-Gallego, R., de la Morena-Barrio, M. E., Vicente, V., Corral, J., and Martínez-Martínez, I. (2014) Role of the C-sheet in the maturation of N-glycans on antithrombin: functional relevance of pleiotropic mutations. J. Thromb. Haemost. 12, 1131–1140
17. Martínez-Martínez, I., Navarro-Fernández, J., Østergaard, A., Gutiérrez-Gallego, R., Padilla, J., Bohdan, N., Miñano, A., Pascual, C., Martínez, C., de la Morena-Barrio, M. E., Águila, S. Pedersen, S., Kristensen, S. R., Vicente, V., and Corral, J. (2012) Amelioration of the severity of heparin-binding antithrombin mutations by posttranslational mosaicism. Blood 120, 900 –904
18. Koide, T., Odani, S., Takahashi, K., Ono, T., and Sakuragawa, N. (1984) Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability. Proc. Natl. Acad. Sci. U.S.A. 81, 289 –293
19. Raja, S. M., Chhablani, N., Swanson, R., Thompson, E., Laffan, M., Lane, D. A., and Olson, S. T. (2003) Deletion of P1 arginine in a novel antithrombin variant (antithrombin London) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis. J. Biol. Chem. 278, 13688 –13695
20. Picard, V., Bura, A., Emmerich, J., Alhenc-Gelas, M., Biron, C., Houbouyan-Reveillard, L. L., Molho, P., Labatide-Alanore, A., Sié, P., Tou-lon, P., Verdy, E., and Aiach, M. (2000) Molecular bases of antithrombin deficiency in French families: identification of seven novel mutations in the antithrombin gene. Br. J. Haematol. 110, 731–734
21. Gettins, P. G. W. (2002) Serpin structure, mechanism, and function. Chem. Rev. 102, 4751– 4804
22. Corral, J., Hernandez-Espinosa, D., Soria, J. M., Gonzalez-Conejero, R., Ordonez, A., Gonzalez-Porras, J. R., Perez-Ceballos, E., Lecumberri, R., Sanchez, I., Roldan, V., Mateo, J., Minano, A., Gonzalez, M., Alberca, I., Fontcuberta, J., and Vicente, V. (2007) Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood 109, 4258 – 4263
23. Mushunje, A., Zhou, A., Carrell, R. W., and Huntington, J. A. (2003) Heparin-induced substrate behavior of antithrombin Cambridge II. Blood 102, 4028 – 4034
24. Dementiev, A., Petitou, M., Herbert, J.-M., and Gettins, P. G. W. (2004) The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity. Nat. Struct. Mol. Biol. 11, 863– 867
25. Peterson, F. C., Gordon, N. C., and Gettins, P. G. W. (2000) Formation of a noncovalent serpin-proteinase complex involves no conformational change in the serpin: use of 1H-15N HSQC NMR as a sensitive nonper-turbing monitor of conformation. Biochemistry 39, 11884 –11892
26. Maddur, A. A., Swanson, R., Izaguirre, G., Gettins, P. G. W., and Olson, S. T. (2013) Kinetic intermediates en route to the final serpin-protease complex: studies of complexes of 1-protease inhibitor with trypsin. J. Biol. Chem. 288, 32020 –32035
27. Carrell, R. W., and Huntington, J. A. (2003) How serpins change their fold for better and for worse. Biochem. Soc. Symp. 163–178
28. Backovic, M., and Gettins, P. G. W. (2002) Insight into residues critical for antithrombin function from analysis of an expanded database of sequences that includes frog, turtle, and ostrich antithrombins. J. Proteome Res. 1, 367–373
29. Irving, J. A., Pike, R. N., Lesk, A. M., and Whisstock, J. C. (2000) Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function. Genome Res. 10, 1845–1864
30. Picard, V., Ersdal-Badju, E., and Bock, S. C. (1995) Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the -antithrombin III isoform with enhanced heparin affinity. Biochemistry 34, 8433– 8440
31. Martínez-Martínez, I., Ordóñez, A., Navarro-Fernández, J., Pérez-Lara, Á, Gutiérrez-Gallego, R., Giraldo, R., Martínez, C., Llop, E., Vicente, V., and Corral, J. (2010) Antithrombin Murcia (K241E) causing antithrombin deficiency:apossibleroleforalteredglycosylation.Haematologica95,1358–1365
32. Turk, B., Brieditis, I., Bock, S. C., Olson, S. T., and Björk, I. (1997) The oligosaccharide side chain on Asn-135 of -antithrombin, absent in -antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change. Biochemistry 36, 6682– 6691
33. Arocas, V., Bock, S. C., Raja, S., Olson, S. T., and Björk, I. (2001) Lysine 114 of antithrombin is of crucial importance for the affinity and kinetics of heparin pentasaccharide binding. J. Biol. Chem. 276, 43809 – 43817
34. Izaguirre, G., Zhang, W., Swanson, R., Bedsted, T., and Olson, S. T. (2003) Localization of an antithrombin exosite that promotes rapid inhibition of factors Xa and IXa dependent on heparin activation of the serpin. J. Biol. Chem. 278, 51433–51440
35. Nordenman, B., Nyström, C., and Björk, I. (1977) The size and shape of human and bovine antithrombin III. Eur. J. Biochem. 78, 195–203
36. Olson, S. T., Björk, I., and Shore, J. D. (1993) Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol. 222, 525–559
37. Yang, L., Manithody, C., and Rezaie, A. R. (2002) Localization of the heparin binding exosite of factor IXa. J. Biol. Chem. 277, 50756 –50760